Why MannKind Could Lose Half Its Value
March 03, 2015 at 10:34 AM EST
When Gilead Sciences (GILD) announced that it would discount Harvoni and Sovaldi by more than 40% due to its price war with AbbVie (ABBV), the hope was that the reductions would be isolated to hepatitis-c treatments. Now, however, Goldman Sachs analyst Jay Olson and team have used potential discounts as the “catalyst” in their downgrade [...]
